Related Experiment Videos
Anti-neuroinflammatory effects of the extract of Achillea fragrantissima
Anat Elmann1, Sharon Mordechay, Hilla Erlank
1Department of Food Quality and Safety, Volcani Center, Agricultural Research Organization, Bet Dagan 50250, Israel. aelmann@volcani.agri.gov.il
Background:
The neuroinflammatory process plays a central role in the initiation and progression of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases, and involves the activation of brain microglial cells. During the neuroinflammatory process, microglial cells release proinflammatory mediators such as cytokines, matrix metalloproteinases (MMP), Reactive oxygen species (ROS) and nitric oxide (NO). In the present study, extracts from 66 different desert plants were tested for their effect on lipopolysaccharide (LPS) - induced production of NO by primary microglial cells. The extract of Achillea fragrantissima (Af), which is a desert plant that has been used for many years in traditional medicine for the treatment of various diseases, was the most efficient extract, and was further studied for additional anti-neuroinflammatory effects in these cells.
Methods:
In the present study, the ethanolic extract prepared from Af was tested for its anti-inflammatory effects on lipopolysaccharide (LPS)-activated primary cultures of brain microglial cells. The levels of the proinflammatory cytokines interleukin1β (IL-1β) and tumor necrosis factor-α (TNFα) secreted by the cells were determined by reverse transcriptase-PCR and Enzyme-linked immunosorbent assay (ELISA), respectively. NO levels secreted by the activate cells were measured using Griess reagent, ROS levels were measured by 2'7'-dichlorofluorescein diacetate (DCF-DA), MMP-9 activity was measured using gel zymography, and the protein levels of the proinflammatory enzymes cyclooxygenase-2 (COX-2) and induced nitric oxide synthase (iNOS) were measured by Western blot analysis. Cell viability was assessed using Lactate dehydrogenase (LDH) activity in the media conditioned by the cells or by the crystal violet cell staining.
Results:
We have found that out of the 66 desert plants tested, the extract of Af was the most efficient extract and inhibited ~70% of the NO produced by the LPS-activated microglial cells, without affecting cell viability. In addition, this extract inhibited the LPS - elicited expression of the proinflammatory mediators IL-1β, TNFα, MMP-9, COX-2 and iNOS in these cells.
Conclusions:
Thus, phytochemicals present in the Af extract could be beneficial in preventing/treating neurodegenerative diseases in which neuroinflammation is part of the pathophysiology.
Insights
The extract of Achillea fragrantissima (Af) significantly reduced nitric oxide (NO) production in activated microglial cells. This desert plant extract also inhibited key inflammatory mediators, showing potential for neurodegenerative disease treatment.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Neuroinflammation, driven by activated microglial cells, is central to neurodegenerative diseases like Parkinson's and Alzheimer's.
- Activated microglia release pro-inflammatory mediators, including nitric oxide (NO), cytokines, and matrix metalloproteinases (MMPs).
- Traditional medicine often utilizes desert plants for therapeutic purposes, necessitating scientific validation.
Purpose of the Study:
- To investigate the anti-neuroinflammatory effects of extracts from 66 desert plants on lipopolysaccharide (LPS)-activated microglial cells.
- To identify specific plant extracts that can inhibit the production of pro-inflammatory mediators.
- To evaluate the efficacy of Achillea fragrantissima (Af) extract in mitigating neuroinflammation.
Main Methods:
- Screening of 66 desert plant extracts for their ability to inhibit LPS-induced NO production in primary microglial cells.
- Detailed analysis of the most potent extract (Af) for its effects on cytokines (IL-1β, TNFα), NO, reactive oxygen species (ROS), MMP-9 activity, and protein levels of COX-2 and iNOS.
- Assessment of cell viability using lactate dehydrogenase (LDH) activity and crystal violet staining.
Main Results:
- Achillea fragrantissima (Af) extract demonstrated the highest efficacy, inhibiting approximately 70% of LPS-induced NO production without compromising cell viability.
- The Af extract significantly suppressed the expression of pro-inflammatory cytokines (IL-1β, TNFα), MMP-9, COX-2, and iNOS.
- These findings highlight the potent anti-neuroinflammatory properties of the Af extract.
Conclusions:
- Phytochemicals within the Achillea fragrantissima (Af) extract possess significant anti-neuroinflammatory potential.
- The Af extract may serve as a valuable therapeutic agent for preventing or treating neurodegenerative diseases characterized by neuroinflammation.
- Further research into Af's active compounds could lead to novel drug development for neurological disorders.
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Drugs Affecting Neurotransmitter Release or Uptake